Table of Contents Table of Contents
Previous Page  50 / 114 Next Page
Information
Show Menu
Previous Page 50 / 114 Next Page
Page Background

50 The US-Israel Legal Review 2019

ISRAEL: MERGERS & ACQUISITIONS

benefits generally applicable to employees under

Israeli law (for example, the benefits conferred by

the Capital Gains track). This means that vesting

will be deemed an ‘exit bonus’, and will be taxed as

ordinary employment income, an outcome that the

management of the target company will consider

unwanted. In particular, ESOP plans which include

vesting treatment of options only upon an exit

event are a desirable feature for private equity

funds that often wish to tie their exit success

with the employees’ awards. As such, the recent

guidelines require careful consideration by private

equity fund and others when structuring future

ESOP plans, as well as a recalculation of currently

adopted schemes. ESOP plans, which are already

very popular in the high-tech sector, are becoming

increasingly commonplace in other industries,

and regard to this issue from the outset will

ensure that employees benefit from their desired

taxation scheme upon the vesting of their options,

thus protecting both the buyer and seller from

potential litigation or increased costs. Moreover,

awareness of these issues whilst structuring deals

is advantageous since amendments or grants are

often required, and the execution of a purchase

agreement before ninety days have lapsed from

such grants and amendments may frustrate

the applicability of the desired tax benefit to

management and employees of the target company.

The ITA provided certain extension and relief so

that by June 2019 companies may act to amend, to

a certain extent, their “non-compliant” ESOP plans.

Thus, we expect companies and private equity

funds, especially those which are on the verge of an

exit, to adjust their equity plans in accordance with

those new guidelines.

Not all regulation creates additional burdens

on companies, however. New rules published by

the Israeli Innovation Authority (IAA) enable both

Israeli and non-Israeli multinational corporations

to license their IAA-funded expertise within their

group entities outside of Israel without incurring

the standard IIA license fees that generally apply.

Instead, the fees that are now being imposed

upon those foreign corporations that own

intellectual property in Israel have been reduced

in a bid to incentivize them to continue to invest

in Israeli technology, by allowing them to share

the technology globally, within their group, at a

reasonable cost. Such grants are commonplace

amongst high-tech companies of all sizes, and

as such these developments will affect mergers

and acquisitions, investments, and commercial

transactions involving IAA-funded companies,

as well as providing an opportunity for those

companies to reconsider the structure of their own

operations in order to share their know-how with

non-Israeli group companies.

Continuing the trend of non-onerous regulation,

we will consider a final piece of legislation that is

likely to be of interest to investors in the Israeli

market; this time, on the antitrust front. Recent

amendments to the Economic Competition Law

have increased the threshold for merger approval

requirements, such that instead of annual aggregate

revenues of NIS 150 million, merger clearance is

now required where the annual aggregate revenues

of the merging companies exceed NIS 360 million

(approximately $100 million). This will considerably

lightentheadministrativeloadonsmallercompanies

conducting a merger, and facilitate swift, decisive

activity by foreign investors and acquirers.

Furthermore, the updated legislation has

considerably widened the scope for ‘self-

assessment’ reliance in relation to antitrust

violations. This allows companies to conduct an

internal risk assessment as to whether a proposed

arrangement falls under the narrowed scope of

‘prohibited restrictive arrangement’ which reduces

the workload of the regulatory authority whilst

We anticipate that the trends such

as sky-high valuations, significant

transaction volume, massive

potential for growth, and a strong

preference for M&A exits as

opposed to IPOs will all continue

into 2019.